Our fictitious severe-asthma biologic, and Genflare's living demonstration of what an AI-native pharma brand.com can be. We build it in the open and keep upgrading it as the tools improve. Here's a first look, and the podcast series that sets the stage.
Leapfrogs the category's dated sites with beautiful, accessible design and a conversational AI guide at its core, for eligibility, coverage, cost, and what to expect.
Everything a brand.com needs, generated and personalized: MOA and mechanism videos, patient and HCP education, access and savings explainers, and the podcast series.
Not a mockup. Real workflows sitting on top of your CRM: PA-intake automation, enrollment, and patient support, the same builds shown in our work samples.
Lumara is not a real medication.
Listen now
An AI-produced competitive intelligence podcast following Lumara's launch into a crowded severe-asthma market. A trailer and eight episodes.
The series overview, an 8-episode TA-specific competitive intelligence podcast produced by Genflare.
Show notes →A fictional once-monthly biologic with dual IL-5 and IL-13 inhibition, poised to enter a crowded severe-asthma market.
Show notes →The real engine of access: how plans decide who gets preferred, who gets blocked, and what it costs to move tiers.
Show notes →The first-fill moment and early adherence: HUB design, copay policy, and specialty-pharmacy handoffs.
Show notes →How existing brands position their value stories to payers, and what it takes to cut through entrenched positioning.
Show notes →Real-world evidence as the currency of access decisions: exacerbations, persistence, and healthcare utilization.
Show notes →Competitive-intelligence maturity: what top teams track, how fast they learn, and why it matters.
Show notes →Borrowing what works in oncology, migraine, and rare disease, and translating those access innovations to Lumara.
Show notes →The launch integration plan: how a specialty biologic turns strategy into day-one execution.
Show notes →We keep building Lumara as the tooling advances. Tell us who you are and we'll share what's next.